Amarin Co. plc (NASDAQ:AMRN) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 17,500,650 shares, a growth of 34.1% from the October 15th total of 13,052,628 shares. Based on an average trading volume of 10,687,612 shares, the days-to-cover ratio is presently 1.6 days. Currently, 6.0% of the company’s stock are short sold.
In other Amarin news, CFO Michael Wayne Kalb sold 150,000 shares of the firm’s stock in a transaction on Monday, September 24th. The shares were sold at an average price of $10.42, for a total transaction of $1,563,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Joseph S. Zakrzewski sold 500,000 shares of the firm’s stock in a transaction on Monday, September 24th. The stock was sold at an average price of $10.60, for a total transaction of $5,300,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 3,016,149 shares of company stock worth $34,812,617 over the last quarter. 4.08% of the stock is owned by company insiders.
Large investors have recently modified their holdings of the company. Signature Estate & Investment Advisors LLC purchased a new stake in shares of Amarin in the third quarter valued at about $137,000. BKS Advisors LLC purchased a new stake in shares of Amarin in the third quarter valued at about $162,000. Trexquant Investment LP purchased a new stake in shares of Amarin in the third quarter valued at about $358,000. MML Investors Services LLC boosted its holdings in shares of Amarin by 66.4% in the third quarter. MML Investors Services LLC now owns 23,336 shares of the biopharmaceutical company’s stock valued at $380,000 after acquiring an additional 9,316 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Amarin by 165.5% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 31,125 shares of the biopharmaceutical company’s stock valued at $506,000 after acquiring an additional 19,400 shares in the last quarter. 39.44% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:AMRN opened at $21.05 on Friday. The stock has a market capitalization of $6.63 billion, a PE ratio of -84.20 and a beta of 0.70. Amarin has a fifty-two week low of $2.35 and a fifty-two week high of $23.33.
Amarin (NASDAQ:AMRN) last issued its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. The firm had revenue of $55.00 million during the quarter, compared to analysts’ expectations of $60.63 million. The firm’s revenue was up 16.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.04) EPS. As a group, sell-side analysts expect that Amarin will post -0.4 EPS for the current year.
Several brokerages have issued reports on AMRN. Zacks Investment Research downgraded shares of Amarin from a “hold” rating to a “sell” rating in a research report on Tuesday, July 24th. BidaskClub downgraded shares of Amarin from a “buy” rating to a “hold” rating in a research report on Thursday. SunTrust Banks raised their price objective on shares of Amarin to $30.00 and gave the stock a “reduce” rating in a research report on Monday, November 5th. HC Wainwright reissued a “positive” rating and set a $31.00 price objective on shares of Amarin in a research report on Friday, November 2nd. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $35.00 price objective on shares of Amarin in a research report on Thursday, November 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Amarin has a consensus rating of “Buy” and a consensus price target of $27.80.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/10/amarin-co-plc-amrn-short-interest-up-34-1-in-october.html.
Amarin Company Profile
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Story: Terms to Better Understand Call Options
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.